摘要
铂类药物是乳腺癌化疗中的常用药物,通过规范化疗方案和合理优化治疗策略,可延长晚期患者的生存时间,改善预后。中国医师协会肿瘤医师分会乳腺癌学组为指导铂类药物在晚期乳腺癌中的临床应用,制定了《铂类药物晚期乳腺癌应用专家共识(2020版)》。本文针对该共识进行解读,为晚期乳腺癌个体化诊疗提供科学依据。
Platinum drug is commonly used in breast cancer patients.It can prolong the survival time and improve the prognosis of advanced patients by standardizing the chemotherapy regimens and optimizing the treatment strategies.In order to guide the clinical application of platinum drugs in patients with advanced breast cancer,the expert committee has reached a consensus.This article aimed to interpret the consensus to provide scientific basis for individualized diagnosis and treatment in advanced breast cancer.
作者
康一坤
袁芃
Yikun Kang;Peng Yuan(Department of Medical Oncology,National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing 100021,China;Department of VIP Medical Services,National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing 100021,China)
出处
《中国肿瘤临床》
CAS
CSCD
北大核心
2022年第6期271-274,共4页
Chinese Journal of Clinical Oncology
关键词
晚期乳腺癌
铂类药物
临床应用
专家共识
advanced breast cancer
platinum-based drugs
clinical application
expert consensus
